Request Demo

Last update 08 May 2025

NCC

Last update 08 May 2025

Basic Info

Synonyms

Na-Cl cotransporter, Na-Cl symporter, NCC

+ [7]

Introduction

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules (PubMed:18270262, PubMed:21613606, PubMed:22009145, PubMed:36351028, PubMed:36792826). Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity).

103

Drugs associated with NCC

Amlodipine Besylate/Chlorthalidone/Telmisartan

Target

AT1R x NCC x VDCCs

Mechanism

AT1R antagonists [+2]

Active Org.

Yuhan Corp.

Originator Org.

Yuhan Corp.

Active Indication

Hypertension

Inactive Indication

Essential Hypertension

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

South Korea

First Approval Date23 Aug 2019

Amlodipine Besylate/Irbesartan/Hydrochlorothiazide

Target

AT1R x NCC x VDCCs

Mechanism

AT1R antagonists [+2]

Active Org.

WinMedica

Originator Org.

WinMedica

Active Indication

Hypertension

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Czechia [+1]

First Approval Date18 Feb 2019

Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril

Target

ACE x COXs x HMGCR x NCC

Mechanism

ACE inhibitors [+3]

Active Org.

Alborz Darou Pharmaceutical Co.

Originator Org.

Alborz Darou Pharmaceutical Co.

Active Indication

Cardiovascular Diseases

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Iran

First Approval Date01 Feb 2018

821

Clinical Trials associated with NCC

NCT05963568

/ Not yet recruitingPhase 3IIT

Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

The overall objective of the Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II (SMAART-II) is to deploy a hybrid study design to firstly, demonstrate the efficacy of a polypill (Polycap ®) containing fixed doses of antihypertensives, a statin, and antiplatelet therapy taken as two capsules, once daily orally in reducing composite vascular risk over 24 months vs. usual care among 500 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, SMAART II seeks to develop an implementation strategy for routine integration and policy adoption of this polypill for post-stroke cardiovascular risk reduction in an under-resourced system burdened by suboptimal care and outcomes.

Start Date01 Jun 2025

Sponsor / Collaborator

Northern California Institute for Research & Education

CTR20251066

/ RecruitingNot Applicable

坎地沙坦酯氢氯噻嗪片（Ⅱ）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验。

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of candesartan cilexetil and hydrochlorothiazide tablets (II) in healthy Chinese subjects under fasting and fed administration conditions.

以药代动力学参数为终点指标，比较空腹和高脂餐后给药条件下，合肥合源药业有限公司生产的坎地沙坦酯氢氯噻嗪片（Ⅱ）与CHEPLAPHARM Arzneimittel GmbH持证的坎地沙坦酯氢氯噻嗪片（Ⅱ）在健康成年人群中吸收程度和速度的差异，对两制剂的生物等效性进行评价。次要目的：评价健康受试者在空腹和高脂餐后给药条件下口服受试制剂坎地沙坦酯氢氯噻嗪片（Ⅱ）和参比制剂坎地沙坦酯氢氯噻嗪片（Ⅱ）的安全性。

[Translation]

The pharmacokinetic parameters were used as the endpoints to compare the differences in the extent and rate of absorption of candesartan cilexetil hydrochlorothiazide tablets (Ⅱ) produced by Hefei Heyuan Pharmaceutical Co., Ltd. and candesartan cilexetil hydrochlorothiazide tablets (Ⅱ) certified by CHEPHAPHARM Arzneimittel GmbH in healthy adults under the conditions of fasting and after a high-fat meal, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of oral administration of the test preparation candesartan cilexetil hydrochlorothiazide tablets (Ⅱ) and the reference preparation candesartan cilexetil hydrochlorothiazide tablets (Ⅱ) in healthy subjects under the conditions of fasting and after a high-fat meal.

Start Date16 Apr 2025

Sponsor / Collaborator

Hefei Cosource Pharmaceuticals, Inc.

CTR20250503

/ CompletedNot Applicable

吲达帕胺缓释片在健康受试者中的随机、开放、两周期、双交叉空腹及餐后生物等效性预试验

[Translation] A randomized, open-label, two-period, double-crossover pilot study of the fasting and fed bioequivalence of indapamide sustained-release tablets in healthy subjects

主要目的：考察空腹及餐后条件下，初步评价吉林天衡英睿制药有限公司研制的吲达帕胺缓释片（规格：1.5mg）与施维雅(天津)制药有限公司持证的吲达帕胺缓释片（商品名：纳催离，规格：1.5mg）在中国健康受试者中的人体生物等效性，为正式试验的方案设计提供依据。次要目的：评价吲达帕胺缓释片受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main purpose: To investigate the human bioequivalence of indapamide sustained-release tablets (specification: 1.5 mg) developed by Jilin Tianheng Yingrui Pharmaceutical Co., Ltd. and indapamide sustained-release tablets (trade name: Nacuili, specification: 1.5 mg) certified by Servier (Tianjin) Pharmaceutical Co., Ltd. in healthy Chinese subjects under fasting and postprandial conditions, and to provide a basis for the design of the formal trial. Secondary purpose: To evaluate the safety of the test and reference preparations of indapamide sustained-release tablets in healthy subjects.

Start Date28 Feb 2025

Sponsor / Collaborator

Jilin Tianheng Yingrui Pharmaceutical Co., Ltd.

100 Clinical Results associated with NCC

100 Translational Medicine associated with NCC

0 Patents (Medical) associated with NCC

2,060

Literatures (Medical) associated with NCC

26 Apr 2025·Japanese Journal of Clinical Oncology

A case of Li–Fraumeni syndrome caused by a 3.6 kb deletion in the TP53 gene suggested by additional data from the NCC Oncopanel

Article

Author: Shirota, Hidekazu ; Ogawa, Maki ; Yasuda, Jun ; Asano, Naoki ; Takeuchi, Mika ; Fujimori, Haruna ; Ito, Shin ; Souma, Satoshi ; Yamaguchi, Kazunori ; Otsuka, Kazunori ; Ohnuki, Koji

AbstractA Japanese woman with Li–Fraumeni syndrome in her 40s underwent comprehensive genetic profiling accompanied by germline data using the Oncoguide NCC Oncopanel, but no germline pathogenic variants in the tumor suppressor gene TP53 were detected. However, careful examination of additional data in the report suggested the presence of a large TP53 deletion. Custom targeting next-generation sequencing and nanopore sequencing revealed a 3.6 kb deletion located between intron 1 and intron 6 of TP53. This finding indicates that the NCC Oncopanel is suggestive for detecting large germline deletions in tumor suppressor genes.

01 Apr 2025·Fish & Shellfish Immunology

Functional study of tilapia T cell activation stimulus signal molecule CD2

Article

Author: Li, Yuan ; Lu, Yi-Shan ; Wang, Zhi-Wen ; Wang, Bei

As a co-stimulatory signaling molecule, CD2 provides a secondary stimulatory signal during T-cell activation. Research on CD2 in lower vertebrates remains limited. In this article, we identify the tilapia CD2 gene (GenBank accession number: OM974656; designated as OnCD2), which is predominantly expressed in various immune tissues of tilapia. Additionally, we determine the interaction between tilapia CD2 and its ligand, CD48. Using the magnetic bead method, we identified the CD2-positive lymphocyte population in tilapia, which primarily includes Th, NCC, and B cells. Under different stimuli, the proportion of CD2-positive cells in the head kidney, peripheral blood, and spleen lymphocytes exhibited varying degrees of increase. Incubation of tilapia lymphocytes with CD2 antibody and CD48 recombinant protein upregulated the expression of genes associated with T cell activation. The results of this study demonstrate that tilapia CD2 not only plays a role in T cell activation through its interaction with the ligand CD48, but also mediates a more complex immune regulation pathway in tilapia. This research serves as a reference for the classification of fish immune cells and enhances our understanding of T cell immunity in fish.

18 Mar 2025·Proceedings of the National Academy of Sciences

Cell extrusion drives neural crest cell delamination

Article

Author: Moore Zajic, Emma L. ; Zhao, Ruonan ; Wood, Christopher ; Yi, Kexi ; Trainor, Paul A. ; McKinney, Mary C.

Neural crest cells (NCC) comprise a heterogeneous population of cells with variable potency that contribute to nearly every tissue and organ throughout the body. Considered unique to vertebrates, NCC are transiently generated within the dorsolateral region of the neural plate or neural tube during neurulation. Their delamination and migration are crucial for embryo development as NCC differentiation is influenced by their final resting locations. Previous work in avian and aquatic species revealed that NCC delaminate via an epithelial–mesenchymal transition (EMT), which transforms these progenitor cells from static polarized epithelial cells into migratory mesenchymal cells with fluid front and back polarity. However, the cellular and molecular mechanisms facilitating NCC delamination in mammals are poorly understood. Through time-lapse imaging of NCC delamination in mouse embryos, we identified a subset of cells that exit the neuroepithelium as isolated round cells, which then halt for a short period prior to acquiring the mesenchymal migratory morphology classically associated with delaminating NCC. High-magnification imaging and protein localization analyses of the cytoskeleton, together with measurements of pressure and tension of delaminating NCC and neighboring neuroepithelial cells, revealed that round NCC are extruded from the neuroepithelium prior to completion of EMT. Furthermore, cranial NCC are extruded through activation of the mechanosensitive ion channel, PIEZO1. Our results support a model in which cell density, pressure, and tension in the neuroepithelium result in activation of the live cell extrusion pathway and delamination of a subpopulation of NCC in parallel with EMT, which has implications for cell delamination in development and disease.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

NCC

Basic Info

Related

Analysis